A clinical study of Low-Dose Lenalidomide as maintenance therapy in elderly patients with primary central nervous system lymphoma who has achieved ≥ partial response (PR) to induction chemotherapy
Latest Information Update: 05 Jan 2021
At a glance
- Drugs Lenalidomide (Primary) ; Pomalidomide (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
Most Recent Events
- 05 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology